Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy

被引：32

作者：

Rios-Tamayo, Rafael ^{[1
,2
,3
,4
]}

Martin-Garcia, Agustin ^{[5
,6
]}

Alarcon-Payer, Carolina ^{[5
]}

Sanchez-Rodriguez, Dolores ^{[1
,7
]}

Maria del Valle Diaz de la Guardia, Ana ^{[5
]}

Garcia Collado, Carlos Gustavo ^{[5
]}

Jimenez Morales, Alberto ^{[5
]}

Jurado Chacon, Manuel ^{[1
,2
,3
,4
]}

Cabeza Barrera, Jose ^{[4
,5
]}

机构：

[1] Univ Hosp Virgen de las Nieves, Monoclonal Gammopathies Unit, Avda Fuerzas Armadas 2, Granada 18014, Spain

[2] Univ Hosp Virgen de las Nieves, Dept Hematol, Granada, Spain

[3] Univ Granada, Genom Oncol Area,GENYO, Ctr Genom & Oncol Res,Pfizer, Andalusian Reg Govt,PTS, Granada, Spain

[4] Univ Granada, Hosp Univ Granada, Inst Invest, Biosanitaria Granada Ibs GRANADA, Granada, Spain

[5] Univ Hosp Virgen de las Nieves, Dept Pharm, Granada, Spain

[6] Univ Hosp Virgen de las Nieves, Clin Trials Unit, Granada, Spain

[7] FIBAO, Granada, Spain

来源：

DRUG DESIGN DEVELOPMENT AND THERAPY | 2017年 / 11卷

关键词：

multiple myeloma; pomalidomide; triplet therapy; dexamethasone; LOW-DOSE DEXAMETHASONE; RISK-STRATIFICATION; OPEN-LABEL; LENALIDOMIDE; SURVIVAL; DRUGS; THALIDOMIDE; EFFICACY; CRITERIA; SAFETY;

D O I：

10.2147/DDDT.S115456

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Multiple myeloma is a very heterogeneous disease with variable survival. Despite recent progress and the widespread use of new agents, patients with relapsed and refractory disease have a poor outcome. Immunomodulatory drugs play a key role in both the front-line and the relapsed/ refractory setting. The combination of pomalidomide (POM) and dexamethasone is safe and effective in relapsed and refractory patients, even in those with high-risk cytogenetic features. Furthermore, it can be used in most patients without the need to adjust according to the degree of renal failure. In order to further improve the results, POM-based triplet therapies are currently used. This article highlights the most relevant issues of POM and POM-based combinations in the relapsed/ refractory multiple myeloma setting, from a pharmacological and clinical point of view.

引用

页码：2399 / 2408

页数：10

共 70 条

[1] Curability of Multiple Myeloma [J].

Alexanian, Raymond ;

Delasalle, Kay ;

Wang, Michael ;

Thomas, Sheeba ;

Weber, Donna .

BONE MARROW RESEARCH, 2012,

[2] Progress and Paradigms in Multiple Myeloma [J].

Anderson, Kenneth C. .

CLINICAL CANCER RESEARCH, 2016, 22 (22) :5419-5427

[3]

[Anonymous], BLOOD

[4]

BADROS AZ, 2016, BLOOD, V128

[5] Curing myeloma at last: defining criteria and providing the evidence [J].

Barlogie, Bart ;

Mitchell, Alan ;

van Rhee, Frits ;

Epstein, Joshua ;

Morgan, Gareth J. ;

Crowley, John .

BLOOD, 2014, 124 (20) :3043-3051

[6] Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma [J].

Baz, Rachid C. ;

Martin, Thomas G., III ;

Lin, Hui-Yi ;

Zhao, Xiuhua ;

Shain, Kenneth H. ;

Cho, Hearn J. ;

Wolf, Jeffrey L. ;

Mahindra, Anuj ;

Chari, Ajai ;

Sullivan, Daniel M. ;

Nardelli, Lisa A. ;

Lau, Kenneth ;

Alsina, Melissa ;

Jagannath, Sundar .

BLOOD, 2016, 127 (21) :2561-2568

[7]

Branca A., 2016, Blood, V128

[8]

BRINGHEN S, 2016, BLOOD, V128

[9] Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma [J].

Chang, Xiubao ;

Zhu, Yuanxiao ;

Shi, Changxin ;

Stewart, A. Keith .

ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2014, 46 (03) :240-253

[10] Cardiac Events in Real-World Multiple Myeloma Patients Treated with Carfilzomib: A Retrospective Claims Database Analysis [J].

Chari, Ajai ;

Aggarwal, Sanjay K. ;

Mezzi, Khalid ;

Wang, Kenneth ;

Kim, Christopher ;

Zhu, Shao ;

Braunlin, Megan ;

Werther, Winifred ;

Mikhael, Joseph .

BLOOD, 2016, 128 (22)

← 1 2 3 4 5 6 7 →